Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation (original) (raw)

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document:http://hdl.handle.net/2445/124236

Títol:	Post-transplantation Cyclophosphamide-based Haploidentical Transplantation As Alternative To Matched Sibling Or Unrelated Donor Transplantation For Hodgkin Lymphoma: A Registry Study Of The Lymphoma Working Party Of The European Society For Blood And Marrow Transplantation
Autor:	Gayoso, Jorge Canals, Carme Finel, Hervé Peggs, Karl Dominietto, Alida Castagna, Luca Afanasyev, Boris Robinson, Stephen P.Blaise, Didier Corradini, Paolo Itala-Rëmës, Maija Bermudez, Arancha Forcade, Edouard Russo, Domenico Potter, Michael N.McQuaker, Grant Yakoub-Agha, Ibrahim Scheid, Christof Bloor, Adrian Montoto Almirall, Silvia Dreger, Peter Sureda, Anna European Society for Blood and Marrow Transplantation
Matèria:	Malaltia de HodgkinTrasplantament d'òrgansHodgkin's diseaseTransplantation of organs
Data de publicació:	20-oct-2017
Publicat per:	American Society of Clinical Oncology
Resum:	Purpose: To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods: We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results: Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P =.04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P =.26) and higher in MUD (P =.003), and risk of relapse was lower in both HAPLO (P =.047) and MUD (P,.001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P =.049) and similar to MUD (38%; P =.59). Conclusion: Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.
Nota:	Reproducció del document publicat a: https://doi.org/10.1200/JCO.2017.72.6869
És part de:	Journal of Clinical Oncology, 2017, vol. 35, num. 30, p. 3425-3435
URI:	https://hdl.handle.net/2445/124236
Recurs relacionat:	https://doi.org/10.1200/JCO.2017.72.6869
Apareix en les col·leccions:	Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Aquest document té tots els drets reservats